The association of deficiency in total body iron with an increased risk of reactive thrombocytosis is well known, but whether 'functional iron deficiency' is also associated with reactive thrombocytosis is unknown. This retrospective case-control study assessed the relationships between functional iron deficiency, reactive thrombocytosis and risk of thromboembolism. A total of 150 patients with reactive thrombocytosis (platelet count >400 x 10 9 /l) and 343 controls (platelet count <400 x 10 9 /l) were selected from the hospital laboratory database system. Patients with haematological disease or recent chemotherapy were excluded. Reactive thrombocytosis, infection, and an elevated C-reactive protein (CRP) concentration were all significantly more common in patients with functional iron deficiency than in those without functional iron deficiency (all P <0.01). After adjusting for infection and CRP concentration, functional iron deficiency was the only marker of iron status significantly associated with reactive thrombocytosis (odds ratio 1.66, 95% confidence interval 1.10-2.75; P=0.048). Thromboembolic events occurred in 32 patients (6.6%). This was not significantly associated with functional iron deficiency. Our results suggest that in patients without haematological malignancy or recent chemotherapy there might be a link between functional iron deficiency and reactive thrombocytosis. Whether treating patients with functional iron deficiency with intravenous iron corrects reactive thrombocytosis without inducing infection remains uncertain, but merits further investigation.
Introduction
An elevated platelet count as a result of acute illness, also called reactive thrombocytosis, is very common in hospitalised patients, especially in critically ill patients after major trauma or infection 1 . Although reactive thrombocytosis has been traditionally considered as innocuous 2 , recent evidence suggested that patients with reactive thrombocytosis from different causes, including iron deficiency, have an increased in vitro thrombotic tendency as well as an increased risk of clinical thromboembolic events 1, [3] [4] [5] . Whether initiating pharmacological thromboprophylaxis or antiplatelet agents for patients with an acute critical illness resulting in reactive thrombocytosis has more benefits than harm is currently unknown.
It is well established that there is a strong association between iron deficiency with low ferritin or total body iron stores and reactive thrombocytosis 2, 5, 6 . While iron deficiency is uncommon in critically ill patients, anaemia as a result of 'functional iron deficiency' or iron-restricted erythropoiesis is prevalent in the critically ill 7 . Functional iron deficiency can be defined as a condition in which a patient has a normal or high ferritin level but with a low or suboptimal iron or transferrin saturation, resulting in a failure of erythropoiesis in the bone marrow 7 . This condition is common in critically ill patients after trauma and infection because, as an acute phase protein, ferritin invariably increases in patients with acute inflammation. This results in a high or normal plasma ferritin concentration even when there is low plasma iron concentration or low total body iron stores with a low plasma iron saturation.
Recent evidence suggested that intravenous iron therapy is effective in increasing haemoglobin concentration in patients with anaemia due to functional iron deficiency 8 , similar to when there is a depletion of total body iron. It is theoretically possible for both functional and absolute iron deficiency to be associated with reactive thrombocytosis. If this is the case, intravenous iron therapy may be useful to reverse reactive thrombocytosis associated with functional iron deficiency, potentially tackling the underlying mechanistic cause of reactive thrombocytosis and reducing the risk of thromboembolism without inducing bleeding, compared to pharmacological thromboprophylaxis.
Anaesth Intensive Care 2016 | 44: 6 We hypothesised that functional iron deficiency is associated with an increased risk of reactive thrombocytosis similar to the situation when there is an absolute deficiency in total body iron 2, 5, 6 . In this case-control study, we assessed the association between functional iron deficiency and reactive thrombocytosis, and whether patients with functional iron deficiency had an increased risk of subsequent venous thromboembolism.
Methods
After obtaining St John of God Subiaco Hospital ethics committee approval (approval number 719), we identified hospital inpatients who were at least 14 years old and had iron studies performed between January of 2009 and June of 2015. In order to be selected for this study, patients needed to have had three blood tests (iron studies, C-reactive protein [CRP] and platelet count) all obtained within the same 24 hour period. Because many patients would have these blood tests performed in the study period, we had used a casecontrol design to establish the link between functional iron deficiency and reactive thrombocytosis. Patients who had a platelet count greater than 400 x 10 9 /l during the study period were all selected as 'cases' and those without a high platelet count were randomly selected as 'controls', using a ratio of 1:3 between the number of cases and controls from the St John of God Subiaco Hospital laboratory result database. In this study, functional iron deficiency was defined as transferrin saturation of less than 20% with a normal or high serum ferritin concentration. Patients were excluded if they had undergone recent chemotherapy (<6 weeks), had disease affecting the bone marrow (e.g. leukaemia, myeloma), or had identified as a Jehovah's Witness.
In addition to these three laboratory results, we also collected data on demographic factors, admission diagnosis, length of hospital stay, hospital mortality, and the occurrence of any thromboembolic event during the same hospitalisation. In the study centre's laboratory, plasma CRP concentration is measured by particle enhanced turbidimetric immunoassay (normal range <8 mg/l). Plasma iron concentration is measured by absorbance, using the chromatic endpoint technique (normal range 9-30 µmol/l). Ferritin is measured by one-step sandwich enzyme immunoassay (normal range 20-500 µg/l dependent on gender and age), and transferrin is measured by quantitative turbidimetric assay using endpoint detection (normal range 1.85-3.65 g/l). Plasma transferrin saturation between 20% and 50% is considered normal.
Statistical analyses
We planned a retrospective case-control study of independent cases and controls with three control subjects per case. Prior data indicate that the probability of having functional iron deficiency in hospitalised patients (i.e. exposure) among controls (without reactive thrombocytosis) is about 0.25. If the true odds ratio for having reactive thrombocytosis in the exposed subjects (with functional iron deficiency) relative to unexposed subjects (without functional iron deficiency) is 1.8 or larger, we would need to study 150 cases of reactive thrombocytosis and 450 control patients to be able to reject the null hypothesis that this odds ratio equals 1 with probability (power) = 0.827 (with a type I error of 0.05).
Categorical and continuous variables with skewed distributions were analysed by chi-square and Mann-Whitney tests, respectively. The relationships between reactive thrombocytosis and different markers of iron status, including presence of functional iron deficiency, plasma ferritin, iron or transferrin concentrations, were then analysed in multivariate logistic regression analyses, while adjusting for severity of inflammation (as reflected by the CRP concentration) and presence of infection. All analyses were two-tailed, conducted by SPSS for Windows (version 23.0, IBM Inc., Armonk, NY, USA), and no predictor was removed in the multivariate analyses. 
Results
Of all the patients selected for the study, a substantial number (n=116) were excluded because the patients had pre-existing haematological disease or recent chemotherapy. Of the 484 patients with (n=150 cases), and without (n=334), reactive thrombocytosis included in this study, 351 patients (72.5%) were found to have functional iron deficiency. The age and gender of patients with and without functional iron deficiency were similar. Reactive thrombocytosis was significantly more common in patients with functional iron deficiency than in those without functional iron deficiency (35.3% versus 19.5%, respectively, absolute risk difference = 15.8%, 95% confidence interval [CI] 6.8-23.6; P=0.001). Infection, increased serum CRP concentration, and a lower plasma ferritin concentration were also significantly associated with functional iron deficiency (all P values <0.01). For patients who had functional iron deficiency, the average length of hospital stay was longer than those without functional iron deficiency (11 versus 7 days, P=0.001), but there were no significant differences in mortality or thromboembolic events (either venous or arterial) between patients with and without functional iron deficiency (Table 1) .
Among all the measures of iron status in the body, only the presence of functional iron deficiency was independently associated with reactive thrombocytosis (odds ratio 1.66, 95% CI 1.01-2.75; P=0.048), after adjusting for infection and CRP concentration ( Table 2) . Combining functional iron deficiency with infection and CRP concentration had a moderate ability to predict presence of reactive thrombocytosis (area under the receiver operating characteristic curve = 0.71, 95% CI 0.66-0.76).
Discussion
In this study we found that functional iron deficiency, as defined by a low transferrin saturation, was the only measure of iron status associated with an increased risk of reactive thrombocytosis. As expected, infection and an elevated CRP were both associated with reactive thrombocytosis. These results have some clinical relevance and warrant further examination.
First, iron deficiency as a cause of reactive thrombocytosis has been well established 2,5,6 . Our findings extend this association further and showed that even in the presence of a normal or high ferritin, functional iron deficiency can still be associated with reactive thrombocytosis. Our results may be explained by the fact that infection invariably increases the level of interleukin-6 (cytokine secreted by T cells and macrophages to stimulate immune response) that will simultaneously activate CRP generation as well as hepcidin 9 . Hepcidin is a 25-amino-acid liver peptide that binds to the ferroportin-1 molecules in the intestine, macrophages and liver, resulting in their cellular internalisation and subsequent loss of function 9 . The result is a decreased release of iron from these cells into the circulation and a decrease in the transferrin saturation 9 . Ferritin, on the other hand, is one of the active phase proteins, which can increase substantially, even in the presence of inadequate plasma and total body iron stores 10, 11 . Our results suggest that functional iron deficiency may be capable of activating the production of thrombopoietin, similar to the situation when there is a depletion in total body iron 2,5,6 , resulting in reactive thrombocytosis.
Second, our multivariate results show that functional iron deficiency might have an independent association with reactive thrombocytosis beyond the effect of infection and severity of inflammation. If this is the case, intravenous iron may be useful in reducing the severity and duration of reactive thrombocytosis in patients with functional iron deficiency, as intravenous iron has been shown to improve plasma iron saturation as well as red blood cell production from the bone marrow in such patients 8 . There is also emerging evidence to suggest that intravenous iron may increase risk of infection 8 . As such, further investigation by an adequately powered randomised controlled study would be needed before intravenous iron could be considered as a viable treatment option for patients with reactive thrombocytosis and functional iron deficiency.
Third, the limitations of this study must be acknowledged. Although previous studies have shown that reactive thrombocytosis is associated with an increased risk of venous thromboembolism and in vitro thrombotic tendency 1, [3] [4] [5] , the small number of patients with such events in the present study limited the power of our analyses. Therefore we could not confirm or exclude true relationships between either reactive thrombocytosis or functional iron deficiency and venous thromboembolism. Furthermore, we lost many of our control patients because they met our exclusion criteria. With a reduction in the number of control patients, the final power of this study to detect our primary endpoint was reduced to 0.80. Insufficient statistical power compromised our multivariate analyses, and if we adjusted the P values of our results by a Bonferroni adjustment, functional iron deficiency would no longer be significantly associated with reactive thrombocytosis (adjusted P value = 0.192). This indicates that our results were imprecise due to the limited sample size of this study. Nevertheless, the magnitude of the mean effect size (odds ratio 1.66) would have clinical relevance if confirmed by larger studies. In addition, our univariate analyses were also suggestive of an association between reactive thrombocytosis or platelet count (as a continuous variable) and functional iron deficiency (Table 1) , making this association less likely to be a spurious result. A larger prospective study is, however, needed to confirm whether functional iron deficiency is a genuine precursor for reactive thrombocytosis and also thrombotic complications 5 . Finally, we did not have data on the hepcidin concentrations in our patients. It is possible that there may be a stronger association between hepcidin and reactive thrombocytosis than between transferrin saturation or functional iron deficiency and reactive thrombocytosis. A recent study has showed that both reactive thrombocytosis and anaemia could be corrected by iron replacement therapy more than by placebo alone in patients with inflammatory bowel disease 12 . Therefore, if we can confirm a strong relationship between plasma hepcidin concentration and reactive thrombocytosis, intravenous iron may present a possible therapy for severe reactive thrombocytosis, provided its benefits are proven to outweigh its possible risks in an adequately powered randomised controlled trial.
In conclusion, this observational study showed that there might be a link between functional iron deficiency and reactive thrombocytosis in patients without haematological malignancy or recent chemotherapy. While this may represent confounding through their mutual associations with infection and inflammation, it is also possible that functional iron deficiency could genuinely induce reactive thrombocytosis similar to the situation when there is a reduction in total iron body stores. Whether treating patients with functional iron deficiency with intravenous iron will correct reactive thrombocytosis, and with benefits outweighing risk of inducing infection remains uncertain, but this merits further investigation.
